E3384-75E
Epilepsy, Progressive Myoclonus Type 2A (Lafora Disease, EPM2A, Laforin, LD, LDE, EPM2, MELF, LAFPTPase, FLJ11207, KIAA0766)
Size
£748.00
- SKU:
- E3384-75E
- Application:
- WB
- Purity:
- Purified by Protein G immunoaffinity chromatography.
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Mouse
- Immunogen:
- Purified, E. coli-derived full length recombinant human Laforin (rhLaforin; aa 1-331; UniProt # O95278).
- Clone:
- 9H116
- Format:
- Supplied as a lyophilized powder from PBS, 5% trehalose. Reconstitute with 200ul sterile PBS.
- Extra Details:
- Laforin, also known as Lafora PTPase and EPM2A, is a 38kD member of the protein tyrosine phosphatase family. Human Laforin is 331 aa in length and contains one carbohydrate binding type-20 (CBM20) domain (aa 1-124) and one tyrosine-protein phosphatase domain (aa 243-311). Multiple splicing variants produce four isoforms of human Laforin, which is most highly expressed in heart, skeletal muscle, kidney, pancreas and brain. It functions as a dual specificity protein phosphatase and may be involved in the control of glycogen metabolism. Mutations in Laforin cause progressive myoclonic epilepsy type 2, also known as Lafora disease. Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
- Shipping Conditions:
- Blue Ice